Director/PDMR Shareholding

 

TIDMGWP 
 
RNS Number : 8539O 
GW Pharmaceuticals PLC 
05 July 2010 
 

 
         GW Pharmaceuticals PLC ("GW Pharmaceuticals" or the "Company") 
 
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS 
Porton Down, UK, 5 July 2010: GW Pharmaceuticals (AIM: GWP) hereby provides 
notification that the Company has today been notified of the following series of 
share transactions, the result of which is an increase in the beneficial 
interests of Dr Geoffrey Guy and Dr Stephen Wright. 
 
The wife of Dr Stephen Wright, Research and Development Director, has today 
purchased 5,000 ordinary shares of 0.1p each at the market price of 110 pence 
per share. This purchase equates to 0.004% of the issued ordinary share capital. 
 
Dr Geoffrey Guy, a Director and Executive Chairman of the Company, has today 
exercised an option to acquire 120,000 ordinary shares of 0.1p each, equating to 
0.09% of the issued ordinary share capital at an exercise price of 36.2 pence 
per share. This follows the sale of 50,000 ordinary shares of 0.1p each on 30th 
June 2010, at the market price of 124 pence; 30,000 ordinary shares of 0.1p each 
on 2nd July 2010 at the market price of 109.6 pence and the sale of 38,678 
ordinary shares of 0.1p each today at the market price of 109 pence per share. 
The total number of shares sold of 118,678 equates to 0.09% of the issued 
ordinary share capital. 
 
Following these notifications Dr Guy's beneficial interest has increased to 
18,345,274 ordinary shares, amounting to 14.11% of the shares in issue, and Dr 
Wright's beneficial interest has increased to 5,000 ordinary shares, amounting 
to 0.004% of the shares in issue. 
 
The total number of shares outstanding in the Company is 130,041,372 ordinary 
shares of 0.1p each. 
 
 
For further information, please contact: 
 
GW Pharmaceuticals PLC                                                +44 
(0)1980 557 000 
Adam George, Company Secretary 
 
Piper Jaffray Ltd (Nominated Adviser) 
Neil Mackison/Rupert Winckler                                          +44  (0) 
203 142 8700 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 RDSLLFVRDSIEIII